22 de mayo de 2017 / 11:46 / hace 4 meses

BRIEF-EyeGate receives milestone payment from Valeant

May 22 (Reuters) - Eyegate Pharmaceuticals Inc:

* EyeGate receives milestone payment from Valeant Pharmaceuticals for EGP-437 for post-operative ocular inflammation and pain in ocular surgery patients

* EyeGate Pharmaceuticals Inc - granted Valeant exclusive, worldwide commercial and manufacturing rights to co’s EyeGate II delivery system and EGP-437 combination product

* EyeGate Pharmaceuticals - co is eligible to receive developmental and sales-based milestones totaling up to about $99.0 million, royalties on valeant’s net sales of product Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below